Cabaletta Bio (CABA) Assets Average (2019 - 2026)
Cabaletta Bio (CABA) posted quarterly Assets Average of $177.4 million for Q4 2025, down 8.89% year-over-year from $194.7 million in Q4 2024, and down 14.34% quarter-over-quarter from $207.1 million in Q3 2025.
Cabaletta Bio (CABA) Assets Average (2019 - 2026) Analysis & Trends
Cabaletta Bio's Assets Average history runs 7 years deep, the most recent figure standing at $177.4 million for Q4 2025.
- In Q4 2025, Assets Average fell 8.89% year-over-year to $177.4 million; the TTM figure through Dec 2025 stood at $177.4 million (down 8.89% YoY), while the FY2025 annual figure was $175.1 million, down 20.19% from the prior year.
- Assets Average for Q4 2025 stood at $177.4 million, down from $207.1 million in the prior quarter.
- The five-year high for Assets Average was $247.1 million in Q1 2024, with the low at $96.8 million in Q3 2022.
- The 5-year median for Assets Average is $159.6 million (2023), against an average of $158.5 million.
- The sharpest annual moves came in 2024 and 2025: Assets Average jumped 124.17% in 2024, then fell 29.13% in 2025.
- Cabaletta Bio's Assets Average stood at $124.5 million in 2021, then fell by 16.2% to $104.3 million in 2022, then soared by 104.63% to $213.5 million in 2023, then declined by 8.78% to $194.7 million in 2024, then dropped by 8.89% to $177.4 million in 2025.
- Business Quant data shows CABA's Assets Average at $177.4 million in Q4 2025, $207.1 million in Q3 2025, and $194.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Cabaletta Bio | 466.25 Mn | 466.25 Mn | - | 210.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 210.91 Mn |
| Dec 31, 2025 | 177.42 Mn |
| Sep 30, 2025 | 207.13 Mn |
| Jun 30, 2025 | 194.82 Mn |
| Mar 31, 2025 | 175.09 Mn |
| Dec 31, 2024 | 194.73 Mn |
| Sep 30, 2024 | 210.91 Mn |
| Jun 30, 2024 | 228.94 Mn |
| Mar 31, 2024 | 247.05 Mn |
| Dec 31, 2023 | 213.47 Mn |
| Sep 30, 2023 | 178.96 Mn |
| Jun 30, 2023 | 144.04 Mn |
| Mar 31, 2023 | 110.21 Mn |
| Dec 31, 2022 | 104.32 Mn |
| Sep 30, 2022 | 96.85 Mn |
| Jun 30, 2022 | 107.84 Mn |
| Mar 31, 2022 | 120.00 Mn |
| Dec 31, 2021 | 124.49 Mn |
| Sep 30, 2021 | 114.78 Mn |
| Jun 30, 2021 | 107.11 Mn |